90 PRECLINICAL STUDIES OF ANA598 COMBINED WITH OTHER ANTI-HCV AGENTS DEMONSTRATE POTENTIAL OF COMBINATION TREATMENT

@article{Thompson200990PS,
  title={90 PRECLINICAL STUDIES OF ANA598 COMBINED WITH OTHER ANTI-HCV AGENTS DEMONSTRATE POTENTIAL OF COMBINATION TREATMENT},
  author={P. A. Thompson and Rupal A Patel and K. Steffy and J. Appleman},
  journal={Journal of Hepatology},
  year={2009},
  volume={50}
}
Background: ANA598 is a novel HCV non-nucleoside polymerase inhibitor currently in clinical development for the treatment of hepatitis C. Due to the high potential for developing resistance to any single direct antiviral used as monotherapy in hepatitis C, future therapies for HCV are expected to involve combinations of direct antivirals to increase antiviral potency and suppress viral resistance. The results from in vitro combination studies provide support for future clinical exploration of… Expand
9 Citations
Review: New direct-acting antivirals in the development for hepatitis C virus infection
  • P. Pockros
  • Medicine
  • Therapeutic advances in gastroenterology
  • 2010
  • 32
Hepatitis C virus-specific directly acting antiviral drugs.
  • 34
  • PDF
New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy
  • 11
Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.
  • H. Li, S. Shi
  • Biology, Medicine
  • Future medicinal chemistry
  • 2010
  • 21
Tissue-Based Model of HCV Replication as a Replacement for Animal Models in Drug Testing
  • 1
  • Highly Influenced
  • PDF
Impact of HCV genetic differences on pathobiology of disease
  • 33